World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 29 January 2018
Main ID:  EUCTR2016-002938-73-NL
Date of registration: 03/10/2016
Prospective Registration: Yes
Primary sponsor: Argenx BVBA
Public title: A Study of the safety and effectiveness of ARGX-113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness
Scientific title: A Randomized, Double blind, Placebo Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX 113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness
Date of first enrolment: 08/12/2016
Target sample size: 24
Recruitment status: Not Recruiting
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 2
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no
Countries of recruitment
Belgium Canada Italy Netherlands Poland Spain Sweden United States
Name: Regulatory   
Address:  Industriepark Zwijnaarde 7, Building C 9052 Zwijnaarde Belgium
Telephone: +329310 3400
Affiliation:  argenx BVBA
Name: Regulatory   
Address:  Industriepark Zwijnaarde 7, Building C 9052 Zwijnaarde Belgium
Telephone: +329310 3400
Affiliation:  argenx BVBA
Key inclusion & exclusion criteria
Inclusion criteria:
1.Have the ability to understand the requirements of the study, provide written informed consent (including consent for the use and disclosure of research-related health information), and comply with the study protocol procedures (including required study visits).
2.Male or female patients aged =18 years.
3.Diagnosis of autoimmune MG with generalized muscle weakness meeting the clinical criteria for diagnosis of MG as defined by the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class II, III or IVa, and likely not in need of a respirator for the duration of the study as judged by the Investigator.
The confirmation of the diagnosis should be documented and supported by:
• Positive serologic test for anti-AChR antibodies before Screening and
• at least 1 of the following 3 tests:
(i) History of abnormal neuromuscular transmission test demonstrated by single-fiber electromyography or repetitive nerve stimulation or
(ii) History of positive edrophonium chloride test, or
(iii) Patient has demonstrated improvement in MG signs on oral cholinesterase inhibitors as assessed by the treating physician.
4.A total score of =5 on the MG ADL at Screening and Baseline with more than 50% of this score attributed to non-ocular items.
5.Patients are required to be on a stable dose of their MG treatment prior to randomization. For patients receiving AZA, other NSIDs, steroids, and/or cholinesterase inhibitors as concomitant medications the following conditions will apply:
•AZA: treatment initiated at least 12 months ago and no dose changes in the last 6 months before Screening.
•Other NSIDs (e.g., methotrexate, cyclosporine, tacrolimus, mycophenolate mofetil, and cyclophosphamide): treatment initiated at least 6 months ago and no dose changes in the last 3 months before Screening.
•Steroids: treatment initiated at least 3 months prior to and no dose changes in the last month before Screening.
•Cholinesterase inhibitors: to be on a stable dose for >2 weeks before Screening.
Note: cholinesterase inhibitors must be held for at least 12 hours consistent with the revised manual for the QMG test as recommended by the Myasthenia Gravis Foundation of America Inc [MGFA]1, before the MGQoL15r, MG ADL, QMG, and MGC assessments.
6.Females of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Visit 1 prior to administration of IMP. Female of childbearing potential are defined as all female participants unless they are postmenopausal (defined by continuous amenorrhea) for at least 2 years with a Follicle stimulating hormone (FSH) >40 IU/L or are surgically sterile (i.e., who had a hysterectomy, bilateral oophorectomy, or have current documented tubal ligation or any other permanent female sterilization procedure). Determination of FSH levels can be used to confirm postmenopausal status in amenorrheic patients not on hormonal replacement therapy if the test result is within the postmenopausal range per the central laboratory.
7.Female participants of childbearing potential must agree to use a highly effective method of contraception (i.e., pregnancy rate of less than 1% per year) during the study and for 90 days after the discontinuation of the IMP. Adequate contraceptive methods include combined hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ov

Exclusion criteria:
1.Females who are pregnant or lactating.
2.MGFA Class I, IVb, and V.
3.Have an active infection, a recent serious infection (i.e., requiring injectable antimicrobial therapy or hospitalization) within the 8 weeks prior to Screening; or history of or known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or Mycobacterium tuberculosis. Patients must have negative test results for HBV surface antigen, HBV core antibody, HCV antibody, HIV 1 and 2 antibodies, and a negative QuantiFERON® TB Gold test at Screening. Patients with an indeterminate QuantiFERON® TB Gold result will be allowed one retest; if not negative on retesting, the patient will be excluded.
4.At Screening, have clinically significant laboratory abnormalities or as below:
•Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >2 x upper limit of normal (ULN).
•Total serum bilirubin of >1.5 x ULN (except for Grade 1 hyperbilirubinemia solely due to a medical diagnosis of Gilbert’s syndrome).
•Serum creatinine >1.5 mg/dL and creatinine clearance <50 ml/min (using the Chronic Kidney Disease Epidemiology [CKD-EPI]-Creatinine formula).
•Clinically significant proteinuria (i.e.,> 3x ULN)
•Hemoglobin =9 g/L
•Thyroid stimulating hormone or thyroglobulin outside of the central laboratory normal range
•International normalized ratio (INR) or activated partial thromboplastin time (aPTT) >1.2x ULN
•Total immunoglobulin G level <6 g/L.
5.Body Mass Index (BMI) at screening = 35 kg/m2.
6.Use of rituximab, belimumab, eculizimab or any monoclonal antibody for immunomodulation within 6 months prior to first dosing. Patients with prior exposure to rituximab must have CD19 counts within the normal range per the central laboratory at Screening.
7.Use of any biological therapy or investigational drug within 3 months or 5 half-lives of the drug (whichever is longer) before Screening.
8.Immunoglobulins given by IV (IVIg), or intramuscular route, or plasmapheresis/plasma exchange (PE) within 4 weeks before Screening.
9.Have known autoimmune disease other than MG that would interfere with the course and conduct of the study (such as uncontrolled thyroid disease or severe RA).
10.Have received vaccinations within 4 weeks before Screening or have any vaccinations planned during the study.
11.Have a history of malignancy, including malignant thymoma, or myeloproliferative or lymphoproliferative disorders at any time, unless deemed cured by adequate treatment with no evidence of recurrence for =5 years before Screening. Patients with completely excised nonmelanoma skin cancers (such as basel cell carcinoma or squamous cell carcinoma) or cervical carcinoma in situ would be permitted at any time.
12.Have a history of cerebrovascular accident or myocardial infarction within the last 12 months before Screening, or current severe/unstable angina, arrhythmia, symptomatic congestive heart failure New York Heart Association (NYHA) class III or IV, or uncontrolled hypertension.
13.Have clinical evidence of significant unstable or uncontrolled acute or chronic diseases (i.e., cardiovascular, pulmonary, hematologic, gastrointestinal, endocrinologic, hepatic, renal, neurologic, malignancy, or infectious diseases) which, in the opinion of the Investigator, could confound the results of the study or put the patient at undue risk.
14.Major past surgery (e.g., heart valve replacement, hip replacement) that, in the opinion of the Inve

Age minimum:
Age maximum:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Myasthenia Gravis who have Generalized Muscle Weakness
MedDRA version: 20.0 Level: PT Classification code 10028417 Term: Myasthenia gravis System Organ Class: 10029205 - Nervous system disorders
Therapeutic area: Body processes [G] - Immune system processes [G12]

Product Name: ARGX-113
Product Code: ARGX-113
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: N/A
CAS Number: 1821402-21-4
Current Sponsor code: ARGX-113
Other descriptive name: ARGX-113
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Concentrate for solution for infusion
Route of administration of the placebo: Intravenous use

Primary Outcome(s)
Main Objective: To evaluate the safety and tolerability of ARGX 113.
Primary end point(s): •Evaluate the incidence and severity of adverse events (AEs) and serious AEs (SAEs).
•Evaluate vital signs, ECG, and laboratory assessments.
Secondary Objective: •To evaluate the clinical effect of ARGX 113 using:
o Myasthenia Gravis Activities of Daily Living (MG ADL) score.
o Quantitative Myasthenia Gravis score (QMG).
o Myasthenia Gravis Composite score (MGC).
•To evaluate the impact of ARGX 113 on quality of life using 15 item quality of life scale for Myasthenia Gravis (MGQoL15r [revised version]).
•To investigate the pharmacokinetics (PK) of ARGX-113.
•To assess the pharmacodynamic (PD) markers (e.g., total immunoglobulin G (IgG) and subtypes, anti acetylcholine receptor [AChR] antibodies).
•To evaluate the immunogenicity of ARGX 113.
Timepoint(s) of evaluation of this end point: Various time points throughout the study
Secondary Outcome(s)
Secondary end point(s): •Score change from Baseline (defined as the score immediately prior to first dose at Visit 1) at Visits 3, 5, 7, 9, 10, 11, 12, 14, and 16 for the following:
o MGQoL15r
•Maximum reduction from Baseline across visit days for MG-ADL, QMG, MGC, and MGQoL15r score.
•Pharmacokinetic parameters of ARGX 113 including maximum observed concentration (Cmax), time of maximum concentration (tmax), concentration prior to dosing (Ctrough), half-life (t1/2,?z), and accumulation ratio (Rac).
•Evaluation of PD markers: total IgG (and subtypes) and anti AChR antibodies.
•Evaluate the incidence of anti drug antibodies (ADA) to ARGX 113.
•Exploratory pharmacogenetic assessments in patients who sign a separate pharmacogenetic ICF to examine FcRn polymorphisms.
Timepoint(s) of evaluation of this end point: Various time points throughout the study
Secondary ID(s)
Source(s) of Monetary Support
Argenx BVBA
Secondary Sponsor(s)
Ethics review
Results available:
Date Posted:
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history